Shares of Ajanta Pharma soared 10 percent to Rs 2,881 in afternoon trade on March 21, marking their fifth straight session of gains and the biggest jump in six weeks, as trading volumes spiked sharply.
As per data on Moneycontrol, about 3 lakh shares changed hands, significantly higher than the one-week average of 83,000 shares and one-month average of 2 lakh shares. Given the recent rally, Ajanta Pharma shares have risen over 10 percent this week.
Follow our LIVE blog for all the latest market updates
Ajanta Pharma reported an 11 percent rise in net profit for the December 2024 quarter, reaching Rs 233 crore, up from Rs 210 crore a year ago. Revenue grew 3.7 percent to Rs 1,146 crore, compared to Rs 1,105.2 crore in the same period last year. EBITDA saw a marginal uptick of 0.2 percent to Rs 320.8 crore, while margins softened slightly to 28 percent from 29 percent in Q3 FY24.
The Mumbai-headquartered company, a specialty pharmaceutical player with a strong branded generics presence in India, Asia, and Africa, operates in over 30 countries.
Also read: SEBI’s new boss clears LG Electronics IPO — indicates shift from speed to stability
In India, its branded generics business outpaced the broader pharmaceutical market, growing 12 percent to Rs 345 crore in Q3 FY25, while nine-month sales climbed 10 percent to Rs 1,083 crore. This growth, surpassing the Indian Pharmaceutical Market’s (IPM) 8 percent rise, was fueled by higher volumes across key therapeutic areas. Dermatology led with a 16 percent increase, followed by pain management and cardiology at 11 percent each, and ophthalmology at 6 percent.
Internationally, the company continued its momentum, with sales in Asia rising 8 percent to Rs 316 crore, and Africa posting a 12 percent jump to Rs 173 crore. The total branded generics business recorded a 10 percent growth in Q3 sales to Rs 834 crore, while nine-month revenue surged 16 percent to Rs 2,588 crore.
In the US, Ajanta’s generics business saw a 4 percent uptick in Q3 sales to Rs 263 crore, with nine-month sales up 3 percent at Rs 723 crore. The company secured five final ANDA approvals and filed four new applications during the period. Of its 51 final approvals, 48 products have been commercialized, with two tentative approvals and 21 awaiting US FDA clearance.
At about 2:40 am, shares of the company were trading at Rs 2,778, higher by 6 percent from the last close on the NSE.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before making any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!